Twitter (TWTR) tanks as Q2 user growth vanishes >>> READ MORE

Obesity Pill Qsymia to Be Covered by Express Scripts

The move will save customers two-thirds off the retail price


prescription drugsVivus (NASDAQ:VVUS) announced on Thursday that Express Scripts (NASDAQ:ESRX) has added its new anti-obesity medication Qsymia as a standard benefit option to its pharmaceutical coverage.

Shares of Vivus climbed more than 2% on the news in Thursday afternoon trading, while Express Scripts shares rose fractionally.

Effective Alzheimer’s Drugs May Be Just Three Years Away
Effective Alzheimer’s Drugs May Be Just Three Years Away

The addition of Qsymia to Express Scripts coverage will cut the drug’s cost by about two-thirds for patients using the pharmacy benefits manager, Reuters noted.

Patients using Qsymia have paid an average of $160 through mail-order distributors. However, Express Scripts will offer it for a co-payment of between $50 and $60.

The drug’s high retail price has been an impediment to its greater use, Vivus noted. Up to 30% of patients who received a Qsymia prescription have opted not to fill it due to the price. Sales have been sluggish due to a lack of benefit coverage.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC